COMPUTATIONAL BIOLOGICAL STUDY OF ARAOMATASE INHIBITORS DOCKING WITH HUMAN PLACENTAL AROMATASE CYTOCHROME P450
Keywords:
Breast cancer, aromatase inhibitors, tamoxifen, arginine(Arg), letrozoleAbstract
Objective: In this current study the pharmacophore of  aromatase inhibitor drugs and tamoxifen, is predicted and is docked with human placental aromatase cytochrome P450
Methods: The tools and software used are Protein Data BanK, to retrieve the structure of the protein; pubchem compound database, to retrieve the chemical structure of the aromatase inhibitors; pharmacophore analysis and the docking analysis using Discovery Studio2.0.
Results: Â The results show that all the drugs are more favorable to bind with arginine (Arg) amino acid present in the active site of the protein. Letrozole shows good binding affinity with active site of the protein.
Conclusion: Among the four drugs, Letrozole shows more dock score of 76.566kcal/mol with internal energy of -9.759. On the other hand, tamoxifen shows least dock score of 48.494 kcal/mol having internal energy of -4.987. Thus, the docking study reveals that aromatase inhibitors drugs are more effective than tamoxifen for treating postmenopausal in women.
Downloads
References
Nguyen DX. Tracing the origins of metastasis. J Pathol 2011;223:195-204.
Sethi N, Kang Y. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat Rev Cancer 2011;11:735-48.
De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008:a review and synthetic analysis. Lancet Oncol 2012;13:607-15.
Fabian CJ. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 2005;23:1644–55.
N Premjanu, C Jaynthy. Tannase production by endophytic Aspergillus niger, Docking studies of Flavonoid derivatives as potent HIV-1 Integrase inhibitors. BMC Infect Disease 2014;14(Suppl 3):E6.
N Premjanu, C Jaynthy. Antidiabetic activity of phytochemical isolated from Lannea Coromendelica leaves–an Insilico approach. Int J Chem Pharm Sci 2014; Special Issue:41-4.
Jaynthy C. Virtual screening of pomegranate (Punica Granatum) chemical constituents for kinase domain of human as a drug target for colon cancer. Int J Pharm Biol Sci 2015;6:(B)752–9.
Dhivya S, Suresh kumar C, Vijayakumar B, Rethavathi J, Karthik ananth C, Jaynthy C. Pharmacophore-based drug designing of metabolite plant axillarin from Inula britannica against native HIV1–Protease. Int J Pharm Biol Sci 2012;3:977–86.
Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286–91.
Dowsett M. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol 1990;32:623–34.
Dowsett M. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005;95:167–72.
Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881-94.
Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 2006:33:7-1.
Miller WR. Aromatase inhibitors and breast cancer. Minerva Endocrinol 2006;31:27-46.
Lonning PE. Pharmacology of new aromatase inhibitors. Breast 1996;5:202-6.
Garrido JMPJ, Garrido EMPJ, Oliveira-Brett AM, Borges F. An electrochemical outlook on tamoxifen biotransformation: current and future prospects. Curr Drug Metab 2011;12:372-82.
F Van Asten K, Neven P, Lintermans A, Wilders H, Paridaens R. Aromatase inhibitors in the breast cancer clinic. Focus Exemestane 2014;21:R31-R49.
Momany FA, Rone RJ. Validation of the general-purpose QUANTA 3.2/CHARMm force field. Comp Chem 1990;13:888-900.
Leis S, Schneider S, Zacharias M. Insilico prediction of binding sites on proteins. Curr Med Chem 2010;17:1550-62.
Dhivya S, Sureshkumar Chinaga, Bommuraj Vijayakumar, Srinivasan Narasimhan. Pharmacophore-based screening of epicatechin against colon cancer. Int J Pharm Sci Drug Res 2012;4:123-5.
Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the european organisation for research and treatment of cancer breast cancer cooperative group. J Clin Oncol 2008;26:4883-90.
H Coombes RC. Aromatase inhibitors and their use in the adjuvant setting, Recent results in cancer research. Fortschritte Der Krebsforschung Progrès Dans Les Recherches Sur le Cancer 1998;152:277-84.
Lamb HM, Adkins JC. Letrozole: a review of use in postmenopausal women with advanced breast cancer. Drugs 1998;56:1125-40.
Løning PE, Eikesdal HP. Aromatase inhibition: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer 2013;20:R183-R201.
Bonneterre J, Buzdar A, Nabholtz JMA, Robertson JFR, Thürlimann B, Von Euler M, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: Results of two randomized trials designed for combined analysis. Cancer 2001;92:2247-58.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-411.